Scott Struthers, Crinetics CEO

Cri­net­ics re­ports sec­ond PhI­II win for acromegaly drug, eyes 2025 launch

Cri­net­ics’ sec­ond Phase III tri­al in­ves­ti­gat­ing its drug pal­tuso­tine in a rare hor­mon­al dis­or­der read out topline da­ta on Tues­day, with the drug notch­ing an­oth­er win by hit­ting its pri­ma­ry and sec­ondary end­points.

In the PATHFN­DR-2 study, Cri­net­ics stud­ied its oral, once-dai­ly drug in 111 par­tic­i­pants with acromegaly who were not phar­ma­co­log­i­cal­ly treat­ed. For the pri­ma­ry end­point, 56% of pa­tients achieved an in­sulin-like growth fac­tor 1 (IGF-1) lev­el less than or equal to 1.0 times the up­per lim­it of nor­mal com­pared to 5% on place­bo, earn­ing a p-val­ue of p<0.0001.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.